Form 4: Cytokinetics CEO Robert Blum Sells 5,000 Shares
SEC Form 4 Filing
Cytokinetics' President and CEO, Robert I. Blum, sold 5,000 shares of common stock at a price of $30.93 on May 16, 2025.
Summary
- Robert I. Blum, President and CEO of Cytokinetics Inc., sold 5,000 shares of common stock on May 16, 2025.
- The sale price was $30.93 per share.
- Following the transaction, Blum directly owns 412,629 shares of Cytokinetics.
- Blum also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of an insider transaction and doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine disclosure of an insider transaction. It's common for executives to periodically sell shares for personal financial management.
Stakeholder Impact
- The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although it is a common practice.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of stock sale transaction. |
Keywords
Cytokinetics, Robert Blum, stock sale, Form 4, insider trading, CYTK, CEO, shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.